Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Tannir

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Cancer Chemotherapy and Pharmacology|January 7, 2010
A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapyP Mathew, N Tannir, S M Tu, et al.
Cancer Treatment Reports|July 1, 1984
Sequential continuous infusion with doxorubicin and vinblastine: an effective chemotherapy combination for patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisoneN Tannir, H Y Yap, G H Hortobagyi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1987
MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's diseaseF B Hagemeister, N Tannir, P McLaughlin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2010
Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinomaD Tsavachidou-Fenner, N Tannir, P Tamboli, et al.
British Journal of Cancer|March 26, 2008
Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findingsE Jonasch, C Wood, P Tamboli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 23, 2009
Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-alpha: association of pretreatment serum levels with survivalA J Montero, C M Diaz-Montero, R E Millikan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 23, 2015
Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumorsY Nieto, S-M Tu, R Bassett, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2015
Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumorsY Nieto, S-M Tu, R Bassett, et al.
Genome Biology|January 5, 2021
Comprehensive integrative profiling of upper tract urothelial carcinomasXiaoping Su, Xiaofan Lu, Sehrish Khan Bazai, et al.
Cancer Immunology, Immunotherapy : CII|February 24, 2023
Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trialA S Feils, A K Erbe, J Birstler, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Cancer Chemotherapy and Pharmacology|January 7, 2010
A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapyP Mathew, N Tannir, S M Tu, et al.
Cancer Treatment Reports|July 1, 1984
Sequential continuous infusion with doxorubicin and vinblastine: an effective chemotherapy combination for patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisoneN Tannir, H Y Yap, G H Hortobagyi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1987
MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's diseaseF B Hagemeister, N Tannir, P McLaughlin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2010
Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinomaD Tsavachidou-Fenner, N Tannir, P Tamboli, et al.
British Journal of Cancer|March 26, 2008
Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findingsE Jonasch, C Wood, P Tamboli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 23, 2009
Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-alpha: association of pretreatment serum levels with survivalA J Montero, C M Diaz-Montero, R E Millikan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 23, 2015
Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumorsY Nieto, S-M Tu, R Bassett, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2015
Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumorsY Nieto, S-M Tu, R Bassett, et al.
Genome Biology|January 5, 2021
Comprehensive integrative profiling of upper tract urothelial carcinomasXiaoping Su, Xiaofan Lu, Sehrish Khan Bazai, et al.
Cancer Immunology, Immunotherapy : CII|February 24, 2023
Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trialA S Feils, A K Erbe, J Birstler, et al.
Pageof 3